FDA adcom backs MRD as new endpoint in multiple myeloma tria

By a unanimous 12-0 vote, the U.S. FDA’s Oncologic Drugs Advisory Committee concluded that new evidence support the use of minimal residual disease (MRD) as an accelerated approval endpoint in multiple myeloma (MM) clinical trials.

Related Keywords

, Oncologic Drugs Advisory Committee , Drugs Advisory Committee , Bioworld , Multiple Myeloma , Hodac , Minimal Residual Disease , Regulatory , Cancer , Us , Fda , Endpoint ,